钠-葡萄糖协同转运蛋白2抑制剂对糖尿病合并心力衰竭的影响

Effect of Sodium-Glucose Cotransporter 2 Inhibitor on Diabetes Mellitus Combined with Heart Failure

钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是近年临床常用的口服降糖药,其可通过抑制肾脏近曲小管SGLT2对葡萄糖的重吸收,促进尿葡萄糖排泄,从而降低血糖水平。糖尿病是心力衰竭的独立危险因素,应用SGLT2抑制剂可显著降低2型糖尿病患者的心力衰竭风险;同时,SGLT2抑制剂还具有独立于血糖控制的防治心力衰竭的作用。因此,SGLT2抑制剂防治心力衰竭的机制已成为目前的研究热点。未来深入研究SGLT2抑制剂对不同类型心力衰竭患者的影响及其具体作用机制,可为糖尿病合并心力衰竭患者的治疗提供新思路。

Sodium-glucose cotransporter 2(SGLT2)inhibitor is an oral hypoglycemic drug commonly used in clinic in recent years.It can inhibit the reabsorption of glucose by SGLT2 in renal proximal convoluted tubules,promote urinary glucose excretion,and lower blood glucose level.Diabetes mellitus is an independent risk factor for heart failure.The use of SGLT2 inhibitors can significantly reduce the risk of heart failure in type 2 diabetes.At the same time,SGLT2 inhibitors can also prevent and treat heart failure independent of blood glucose control.Therefore,the mechanism of SGLT2 inhibitor in the prevention and treatment of heart failure has become a research hotspot.Further studies on the effects of SGLT2 inhibitors on different types of heart failure patients and their specific mechanisms may provide new ideas for the treatment of diabetes patients with heart failure.